Trials

TASTE (Fröbert), 2013 (NCT01093404) thrombectomy versus PCI only in patients with STEMI undergoing PCI

INFUSE AMI, 2013 thrombectomy versus conventional PCI in patients with ST-segment-elevation myocardial infarction caused by proximal or mid left anterior descending artery occlusion undergoing primary percutaneous coronary intervention with bivalirudin anticoagulation

IABP SHOCK II, 2012 (NCT00491036) IABP versus non-IABP in patients with cardiogenic shock complicating acute myocardial infarction

Ciszewski, 2011 thrombectomy versus conventional PCI in high risk patients with STEMI and angiographic evidence of thrombus

JETSTENT, 2010 AnjioJet versus conventional PCI in patients with ST-elevation MI and at least moderate thrombus burden

Wohrle, 2010 error versus error in

HEBE III, 2010 epoetin alfa versus placebo in patients with a first ST-elevation MI and a successful PCI

NORDISTEMI, 2009 (NCT00161005) thrombolysis + angioplasty versus immediate thrombolysis in patients with STEMI of less than 6 hours of duration and more than 90 minutes expected time delay to PCI

TRIANA, 2009 (NCT00257309) primary ballon angioplasty versus tenecteplase in >=75 years old with ST-segment elevation or LBBB AMI <6 hours of evolution without contraindications for thrombolytic therapy

BALANCE, 2009 autologous bone marrow stem cells versus control in

RECOVER 2, 2009 (NCT00972270) error versus error in

IRIS, 2009 (NCT00157768) early implantation of ICD after MI versus control in patients patients at increased risk 5 to 31 days after AMI

HeartMate II, 2009 (NCT00121485) continuous-flow HeartMate II versus pulsatile-flow HeartMate XVE in patients with advanced heart failure not eligible for heart transplantation

ERASE-MI, 2009 elinogrel versus placebo in STEMI patients

Hare , 2009 versus in

PREPARE, 2009 error versus error in

Liistro, 2009 thrombectomy versus conventional PCI in patients with ST-segment elevation myocardial infarction

Lipiecki, 2009 Export versus conventional PCI in

Horizons, 2008 (NCT00433966) bivalirudin versus in STEMI patients within 12 hours of symptom onset who were undergoing primary PCI

FINESSE (combination-facilitated PCI), 2008 (NCT00046228) Abciximab + reteplase versus primary intervention in patients with acute ST-segment elevation myocardial infarction; symptom duration <6h

TAPAS, 2008 (ISRCTN16716833) Export versus conventional PCI in patients with myocardial infarction

TRANSFER-AMI, 2008 (NCT00164190) thrombolysis + angioplasty versus immediate thrombolysis in patients with high-risk STEMI

CARESS, 2008 thrombolysis + angioplasty versus immediate thrombolysis in STEMI patients under 75 years old within 12 hours of symptom onset who had been admitted to hospitals without PCI facilities

CARESS-in-AMI, 2008 versus in

Export (Chevalier), 2008 Export versus conventional PCI in patients with acute myocardial infarction

DEDICATION, 2008 FilterWireg versus conventional PCI in patients with STEMI referred within 12 h to have PCI

Tahk, 2008 GuardWire versus conventional PCI in AMI patients presenting within 12 h of onset of symptoms

Seyfarth, 2008 Impella LP2.5 versus intra-aortic balloon pump in patients with cardiogenic shock

ASPARAGUS, 2008 Guardwire versus conventional PCI in patients with acute myocardial infarction

Chao, 2008 thrombectomy versus conventional PCI in STEMI patients within 12 h from onset

OASIS 6, 2007 (NCT00064428) GIK infusion versus control in patients with acute STEMI

Glucose-insulin-potassium study II, 2007 GIK infusion versus control in STEMI patients without signs of heart failure

MICADO, 2007 GuardWire versus conventional PCI in Patients with AMI within 24 hours from onset

UpFlow MI, 2007 FilterWire versus conventional PCI in patients with STEMI and coronary angiographic evidence of thrombotic occlusion

PREMIAR, 2007 SpideRX versus conventional PCI in with acute ST-segment elevation myocardial infarction at high risk of embolic events (including only baseline Thrombolysis In Myocardial Infarction grade 0 to 2 flow)

Ochala, 2007 GuardWire versus conventional PCI in patients with ST elevation acute myocardial infarction referred for primary percutaneous coronary intervention

MAGIC 1 (Kang), 2007 G-CSF versus control in patients with myocardial infarction

Takano, 2007 G-CSF versus control in patients with AMI related with the left anterior descending coronary artery, who underwent successful percutaneous coronary intervention

RIGENERA (Leone), 2007 G-CSF versus control in patients with large anterior wall AMI at high risk of unfavorable remodeling and with successful primary or rescue percutaneous coronary intervention and LVEF<50%

Suarez de Lezo (G-CSF), 2007 G-CSF versus control in patients with revascularized anterior wall AMI and depressed left ventricular function (ejection fraction < 45%)

Suarez de Lezo (cell), 2007 autologous bone marrow stem cells versus control in patients with revascularized anterior wall AMI and depressed left ventricular function (ejection fraction < 45%)

Li, 2007 autologous bone marrow stem cells versus control in patients with AMI

Penicka, 2007 autologous bone marrow stem cells versus control in patients with large anterior acute myocardial infarction

OAT, 2006 late PTCA versus no PTCA in stable patients who had total occlusion of the infarct-related artery 3 to 28 days after myocardial infarction and who met a high-risk criterion (

TOSCA-2, 2006 (NCT00025766) late PTCA versus no PTCA in patients with an occluded native infarct-related artery 3 to 28 days after MI

CREATE-ECLA , 2006 GIK infusion versus control in patients with STEMI within 12 hours of symptom onset

Bucciarelli-Ducci , 2006 GIK infusion versus placebo in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

ASSENT-4 PCI (Van de Werf), 2006 (NCT00168792) versus primary intervention in symptom duration <6 h

Bellandi, 2006 Abciximab versus primary intervention in symptom duration <6h

WEST, 2006 systematic PCI (+stent) versus no systematic PCI in STEMI patients (> 4 mm ST-elevation/deviation) within 6 h of symptom onse

HIS, 2006 versus in

DEAR-MI, 2006 (NCT00257153) Pronto versus conventional PCI in patients with STEMI, admitted within 12 h of symptom onset

De Luca, 2006 Diver versus conventional PCI in patients with anterior ST elevation myocardial infarction

Kaltoft, 2006 Rescue versus conventional PCI in patients with ST-segment-elevation myocardial infarction lasting <12 hours undergoing primary PCI

AiMI, 2006 AngioJet versus conventional PCI in patients presenting within 12 h of symptom onset

ExTRACT-TIMI25, 2006 (NCT00077792) enoxaparin versus unfractionated heparin in patients with acute ST-segment elevation myocardial infarction who are eligible to receive fibrinolytic therapy

REVIVAL-2 (Zohlnhöfer ), 2006 (NCT00126100) G-CSF versus placebo in patients with acute myocardial infarction after successful mechanical reperfusion reduces infarct size

STEMMI (Ripa), 2006 G-CSF versus placebo in patients with ST-elevation myocardial infarction

G-CSF-STEMI (Engelmann), 2006 G-CSF versus placebo in patients with late revascularized subacute STEMI

MAGIC Cell-3-DES (Kang), 2006 G-CSF versus control in patients with recent or old myocardial infarction who underwent coronary revascularization with DES

Ellis, 2006 (NCT00215124) G-CSF versus placebo in patients with large acute myocardial infarction

TCT-STAMI (Ge), 2006 autologous bone marrow stem cells versus control in patients admitted within 24 h after the onset of a first AMI

Huang, 2006 autologous bone marrow stem cells versus control in patients with first onset of acute inferior-wall myocardial infarction aged < or = 75, treated with emergent percutaneous coronary intervention

Janssens, 2006 autologous bone marrow stem cells versus placebo in patienst with successful percutaneous coronary intervention for STEMI

MAGIC Cell-3-DES (Kang), 2006 autologous bone marrow stem cells versus control in patients with myocardial infarction who underwent coronary revascularization with DES for the culprit lesion

ASTAMi (Lunde), 2006 autologous bone marrow stem cells versus control in patients with acute ST-elevation myocardial infarction of the anterior wall treated with percutaneous coronary intervention

Meluzin LD, 2006 autologous bone marrow stem cells versus control in patients with a first acute myocardial infarction

Meluzin HD, 2006 autologous bone marrow stem cells versus control in patients with a first acute myocardial infarction

REPAIR-AMI (Schachinger), 2006 (NCT00279175) autologous bone marrow stem cells versus placebo in patients with acute myocardial infarction

Suzuki, 2006 G-CSF versus control in patients with angina or AMI

Deng, 2006 G-CSF versus control in

Burkhoff, 2006 TandemHeart versus intra-aortic balloon pump in patents within 24 hours of developing cardiogenic shock

MICHELANGELO OASIS-6, 2006 (NCT00064428) fondaparinux versus placebo in patients with STEMI

COMMIT, 2005 (NCT00222573) immediate metoprolol versus placebo in patients within 24 h of suspected acute MI onset

COMMIT, 2005 (NCT00222573) clopidogrel versus placebo in patients admitted to hospital within 24 h of suspected acute MI onset

Silva et al, 2005 late PTCA versus no PTCA in patients with occluded infarct-related artery between 12 h and 14 days post-anterior MI were

Krljanac, 2005 GIK infusion versus control in patients with ST-elevation myocardial infarction within 12 hours from symptom onset

INTAMI (Zeymer), 2005 Eptifibatide versus primary intervention in symptom duration <12h

ADVANCE-MI, 2005 Eptifibatide + tenecteplase versus primary intervention in symptom duration <4h

CREATE, 2005 Reviparin versus placebo in patients with acute myocardial infarction, STEMI or new LBBB, <=12 h

REACT (rescue PCI), 2005 rescue PTCA versus no rescue PTCA in patients with ST-segment elevation myocardial infarction and failed reperfusion (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment

REACT (repeat fibrinolysis), 2005 repeat fibrinolysis versus no repeat fibrinolysis in patients with ST-segment elevation myocardial infarction and failed reperfusion (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment

CAPITAL AMI, 2005 thrombolysis + angioplasty versus immediate thrombolysis in high-risk MI patients within six hours of symptom onset

CAPITAL AMI, 2005 systematic PCI (+stent) versus no systematic PCI in patients with high-risk ST-segment elevation myocardial infarction

ZWOLLE 6, 2005 primary stenting versus balloon angioplasty in unselected patients with STEMI

REMEDIA, 2005 Diver versus conventional PCI in patients with ST-segment elevation acute myocardial infarction

Noel, 2005 Export versus conventional PCI in patients with acute myocardial infarction

EXPIRA, 2005 Export versus conventional PCI in patients with acute myocardial infarction

Sardella, 2005 Diver versus conventional PCI in patients with acute myocardial infarction

X AMINE ST, 2005 X-sizer versus conventional PCI in patients with AMI <12 h and initial TIMI flow grade 0 to 1 and who were treated by PCI

PROMISE, 2005 FilterWire versus conventional PCI in patients with myocardial infarction with and without ST-segment elevation

EMERALD, 2005 GuardWire versus conventional PCI in patients with ST-segment elevation myocardial infarction presenting within 6 hours of symptom onset and undergoing primary PCI or rescue intervention after failed thrombolysis

FIRSTLINE-AMI (Ince), 2005 G-CSF versus control in patients with ST-elevation myocardial infarction undergoing primary PCI with stenting and abciximab

Valgimigli, 2005 G-CSF versus placebo in patients with STEMI

senior PAMI, 2005 (NCT00136929) primary PCI versus Thrombolysis in elderly (age >= 70 years) patients with acute myocardial infarction

Karpov, 2005 autologous bone marrow stem cells versus control in patients with acute myocardial infarction.

Ruan, 2005 autologous bone marrow stem cells versus control in with acute myocardial infarction and anterior descending coronary artery occlusion proven by angiography

INTAMI, 2005 (NCT00251823) early eptifibatide versus late or no eptifibatide in patients with ST elevation myocardial infarction <12 h scheduled for primary percutaneous intervention

REACT (rescue PCI vs repeat fibrinolysis), 2005 rescue PTCA versus repeat fibrinolysis in patients with ST-segment elevation myocardial infarction and failed reperfusion (less than 50 percent ST-segment resolution) within 90 minutes after thrombolytic treatment

Thiele, 2005 TandemHeart versus intra-aortic balloon pump in patients in cardiogenic shock following acute myocardial infarction

CLARITY-TIMI 28, 2005 clopidogrel versus placebo in patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction

DECOPI, 2004 late PTCA versus no PTCA in patients with a first Q-wave myocardial infarction and an occluded infarct vessel

Zibaeenezhad, 2004 warfarin versus control (on top of aspirin) in Acute MI

GRACIA (Fernandez-Aviles,), 2004 tenecteplase versus primary intervention in symptom duration <12h

On-Time (van’t Hof), 2004 Tirofiban versus primary intervention in symptom duration <6h

ReoPro-BRIDGING (Gyongyosi), 2004 Abciximab versus primary intervention in symptom duration <6h

BRAVE (Kastrati), 2004 Abciximab + reteplase versus primary intervention in symptom duration <12h

LoWASA, 2004 warfarin versus control (on top of aspirin) in AMI

Nakashima, 2004 magnesium versus placebo in patients with successful PCI weree, imag

Nameki, 2004 magnesium versus in

MERLIN, 2004 rescue PTCA versus no rescue PTCA in patients with STEMI and failed fibrinolysis

GRACIA-1, 2004 systematic PCI (+stent) versus no systematic PCI in patients with thrombolysed STEMI (with recombinant tissue plasminogen activator)

Kurihara à effacer, 2004 versus in patients with a first AMI within 6 hours of onset

MERLIN (Sutton), 2004 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with STEMI and failed fibrinolysis

STOPAMI 3, 2004 primary stenting versus balloon angioplasty in patients with AMI ineligible for thrombolysis (lack of ST-segment elevation on the electrocardiogram, late presentation >12 h after symptom onset, and contraindications to thrombolysis)

STOPAMI 4, 2004 versus balloon angioplasty in patients with AMI referred for failed thrombolysis performed within the previous 24 h

Dudek, 2004 Rescue versus conventional PCI in patient with acute myocardial infarction with ST segment elevation

PIHRATE, 2004 Diver versus conventional PCI in patients with acute myocardial infarction

VAMPIRE, 2004 TVAC versus conventional PCI in patients with acute myocardial infarction

NONSTOP, 2004 Rescue versus conventional PCI in patients with acute myocardial infarction

Florence, 2004 AngioJet versus conventional PCI in patients with a first acute myocardial infarction

DIPLOMATE, 2004 Angioguard versus conventional PCI in patients with acute myocardial infarction

MAGIC (G-CSF) (Kang), 2004 G-CSF versus control in patients with myocardial infarction who underwent coronary stenting for the culprit lesion of infarction

MAGIC (cell infusion ), 2004 autologous bone marrow stem cells versus control in patients with myocardial infarction who underwent coronary stenting for the culprit lesion of infarction

BOOSt (Meyer), 2004 autologous bone marrow stem cells versus control in successful percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction

Nanasato, 2004 Guardwire versus conventional PCI in patients with acute myocardial infarction

Chen, 2004 autologous bone marrow stem cells versus control in

ACE, 2003 Abciximab versus in patients with AMI

Petronio, 2003 Abciximab versus control in

VALIANT (valsartan alone), 2003 Valsartan versus Captopril in patients within 10 days of a MI complicated by HF

VALIANT (valsartan+capropril), 2003 Valsartan+ACE inhibitor versus ACE inhibitor only in patients within 10 days of a MI complicated by HF

TIGER-PA (Lee), 2003 Tirofiban versus primary intervention in symptom duration <12h

ERAMI (Mesquita Gabriel), 2003 Abciximab versus primary intervention in symptom duration <12h

REOMOBILE (Arntz), 2003 Abciximab versus primary intervention in symptom duration <6h

Cutlip, 2003 Tirofiban versus primary intervention in symptom duration <12h

ASSENT Plus, 2003 Dalteparin versus UFH in Patients with AMI treated with alteplase

ASSENT 3 Plus, 2003 Enoxaparin versus UFH in patients with ST-elevation myocardial infarction

DANAMI-2, 2003 primary angioplasty versus immediate thrombolysis in patients with myocardial infarction with ST-segment elevation

PRAGUE-2, 2003 primary angioplasty versus immediate thrombolysis in patients with acute ST elevation myocardial infarction presenting within <12 h to the nearest community hospital without a catheter laboratory

DANAMI-2 , 2003 transfer for primary angioplasty versus immediate thrombolysis in patients with myocardial infarction with ST-segment elevation

PRAGUE-2 , 2003 transfer for primary angioplasty versus immediate thrombolysis in patients with acute ST elevation myocardial infarction presenting within <12 h to the nearest community hospital without a catheter laboratory

Napodano, 2003 X-sizer versus conventional PCI in patients with AMI and angiographic evidence of intraluminal thrombus

Wang, 2003 Angioguard versus conventional PCI in patients with acute myocardial infarction

CADILLAC, 2002 Abciximab versus in patients with acute myocardial infarction

Petronio, 2002 Abciximab versus placebo in rescue PTCA within 24 hours from the onset of chest pain

Zoman, 2002 Abciximab versus placebo in

ENTIRE-TIMI23, 2002 Abciximab versus in

GUSTO V, 2002 Abciximab versus in

Stone (CADILLAC), 2002 stent versus fibrinolysis in

OPTIMAAL, 2002 Losartan versus Captopril in patients within 10 days of a confirmed acute myocardial infarction and heart failure during the acute phase or a new Q-wave anterior infarction or reinfarction

TOAT, 2002 late PTCA versus no PTCA in symptom-free patients after acute myocardial infarction

APRICOT-2, 2002 warfarin versus control (on top of aspirin) in Acute MI after thrombolytics

ASPECT-2 (coumadin alone), 2002 coumadin versus aspirin in Acute MI, unstable angina

WARIS II (warfarin alone), 2002 warfarin versus aspirin in patients hospitalized for acute myocardial infarction

Zorman, 2002 Abciximab versus primary intervention in symptom duration <12h

CHAMP, 2002 warfarin versus control (on top of aspirin) in AMI (patients enrolled within 14 days of infarction)

ASPECT-2 (coumadin+ASA vs ASA), 2002 coumadin versus control (on top of aspirin) in Acute MI, unstable angina

WARIS II (warfarin+ASA), 2002 warfarin versus control (on top of aspirin) in patients hospitalized for acute myocardial infarction

Baird, 2002 Enoxaparin versus UFH in patients receiving fibrinolytic therapy following acute myocardial infarction

ENTIRE-TIMI 2, 2002 Enoxaparin versus UFH in Patients with ST-elevation MI presenting <6 hours from symptom onset were

AMI-SK, 2002 Enoxaparin versus placebo in patients with evolving myocardial infarction, Age >=18 y, STEMI

Zhu, 2002 magnesium versus control in AMI

SIAM III, 2002 systematic PCI (+stent) versus no systematic PCI in patients receiving thrombolysis in AMI (<12 h)

CADILLAC abciximab., 2002 primary stenting versus balloon angioplasty in patients with acute myocardial infarction

CADILLAC (no abciximab), 2002 primary stenting versus balloon angioplasty in patients with acute myocardial infarction

AIR-PAMI, 2002 primary angioplasty versus immediate thrombolysis in Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg), eligible for thrombolytic therapy

CAPTIM, 2002 primary angioplasty versus immediate thrombolysis in patients within 6 h of acute myocardial infarction with ST-segment elevation, initially managed by mobile emergency-care units

AIR-PAMI , 2002 transfer for primary angioplasty versus immediate thrombolysis in Patients with high-risk AMI (age >70 years, anterior MI, Killip class II/III, heart rate >100 beats/min or systolic BP <100 mm Hg), eligible for thrombolytic therapy

C-PORT, 2002 primary PCI versus accelerated t-PA in thrombolytic-eligible patients with acute MI of less than 12 hours' duration associated with ST-segment elevation

STOPAMI 2, 2002 primary stenting versus immediate thrombolysis in patients with acute myocardial infarction within 12 h of onset of symptoms

Beran, 2002 X-sizer versus conventional PCI in patients with ACS and suspected intracoronary thrombus

Wagner, 2002 ramipril versus placebo in patients with acute myocardial infarction

ADMIRAL, 2001 Abciximab versus placebo in patients with acute myocardial infarction

ASSENT III, 2001 Abciximab versus in

PSSAAMI (Scheller), 2001 primary stenting versus balloon angioplasty in patients within 24 hours after the onset of acute myocardial infarction

Huynh, 2001 versus control (on top of aspirin) in CABG patients with unstable angina or non–Q-wave MI

OASIS main, 2001 versus control (on top of aspirin) in Unstable angina, non–Q-wave MI

ASSENT 3, 2001 Enoxaparin versus UFH in patients with acute myocardial infarction

HART II, 2001 Enoxaparin versus UFH in patients undergoing reperfusion therapy with an accelerated recombinant tissue plasminogen activator regimen and aspirin for AMI

combined TIMI 10B–TIMI 14 (Schweiger), 2001 versus in

STAT, 2001 primary stenting versus accelerated t-PA in patients with acute ST-elevation myocardial infarction

Kimura , 2001 versus in

InTIME-II, 2000 lanoteplase versus accelerated t-PA in patients presenting within 6 h of onset of ST elevation acute myocardial infarction

ISAR-2, 2000 Abciximab versus control (on top stenting) in Patients undergoing stenting within 48 h after onset of AMI

STENTIM-2 (Maillard), 2000 primary stenting versus balloon angioplasty in patients with AMI <12 h from symptom onset, with an occluded native coronary artery

PRAGUE (Widimisky), 2000 streptokinase versus primary intervention in symptom duration <6h

MAGIC, 2000 (NCT00000610) magnesium versus placebo in AMi patients within 6 h of onset of symptomsm

Gyamlani, 2000 magnesium versus placebo in patients with proven AMI

Santoro, 2000 magnesium versus placebo in

RESCUE II, 2000 rescue PTCA versus no rescue PTCA in patient with TIMI II flow after fibrinolytic therapy for moderate to large MI

Sarullo, 2000 repeat fibrinolysis versus no repeat fibrinolysis in patients with large AMI and failed thrombolysis

SPEED (Phase A), 2000 versus in patients with acute MI <=12 hours after chest-pain onset

PRAGUE, 2000 systematic PCI (+stent) versus no systematic PCI in patients with acute ST elevation myocardial infarction presenting to community hospitals

SPEED (GUSTO-4 pilot) Hermann, 2000 versus in

PRAGUE-1, 2000 primary angioplasty versus immediate thrombolysis in patients with acute myocardial infarction, presenting within 6 h of symptom onset at community hospitals without a catheterization laboratory

PRAGUE-1 (thrombolysis+PTCA), 2000 thrombolysis + angioplasty versus immediate thrombolysis in patients with acute myocardial infarction, presenting within 6 h of symptom onset at community hospitals without a catheterization laboratory

STOPAMI 1, 2000 facilitated stenting versus alteplase in patients with acute myocardial infarction

SPEED (Phase B), 2000 error versus error in patients with acute myocardial infarction

SPEED (Phase B) importé, 2000 Abciximab versus control (on top reteplase) in patients with acute myocardial infarction

SPEED (Phase A) importé, 2000 Abciximab+reteplase versus Abciximab in patients with acute MI <=12 hours after chest-pain onset

ASSENT-2, 1999 tenecteplase versus accelerated t-PA in patients with acute myocardial infarction of less than 6 h duration

stent-PAMI (Grines), 1999 primary stenting versus balloon angioplasty in patients with acute myocardial infarction and with vessels suitable for stenting

PASTA (Saito), 1999 primary stenting versus balloon angioplasty in patients with AMI within 12 hr from onset

PRISAM (Kawashima), 1999 primary stenting versus balloon angioplasty in

LIMI (Vermeer), 1999 alteplase versus primary intervention in symptom duration <6h

PACT (Ross,), 1999 alteplase versus primary intervention in symptom duration <6h

WARIS, 1999 warfarin versus control (on top of aspirin) in survivors of acute myocardial infarction

BIOMACS II, 1999 Dalteparin versus placebo in patients with acute myocardial infarction, Age <=80 y, STEMI or new LBBB

Raghu, 1999 magnesium versus placebo in confirmed AMI < 6 h from the onset of symptomsce

French, 1999 captopril versus placebo in patients aged < or = 75 years with first infarctions, presenting within 4 h of symptom onset

SHOCK (Hochman), 1999 (NCT00000552) immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with cardiogenic shock complicating acute MI

Vermeer, 1999 systematic ballon angioplasty versus no systematic angioplasty in patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities

PACT (Ross), 1999 versus in

LIMI (Vermeer), 1999 versus in patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities.

SWISS-SMASH, 1999 immediate systematic ballon angioplastyte versus no immediate angioplasty in Patients with acute myocardial infarction and early shock

Vermeer, 1999 rescue PTCA versus no rescue PTCA in patients admitted to hospitals without angioplasty facilities

MAASTRICHT (Vermeer), 1999 primary angioplasty versus immediate thrombolysis in patients with acute myocardial infarction initially admitted to a hospital without PTCA facilities

ASSENT-1, 1999 tenecteplase versus in

COMPASS, 1998 saruplase versus streptokinase in patients with symptoms compatible with those of acute myocardial infarction for < 6 h

Rapport, 1998 Abciximab versus placebo in primary angioplasty for acute myocardial infarction

Jaksch, 1998 primary stenting versus balloon angioplasty in

GRAMI (Rodriguez), 1998 primary stenting versus balloon angioplasty in patients with acute myocardial infarction within 24 hours after onset

Zwolle 5 (Suryapranata), 1998 primary stenting versus balloon angioplasty in Patients with acute myocardial infarction

Horie et al, 1998 late PTCA versus no PTCA in patients with initial Q-wave anterior myocardial infarction >24 hours after onset

OASIS pilot, 1998 any anticoagulant versus in Unstable angina, non–Q-wave MI

FAMIS, 1998 fosinopril versus placebo in patients with anterior acute myocardial infarction within 9 hours of onset

FRESCO, 1998 primary stenting versus balloon angioplasty in patient with successful primary PTCA

TIMI 10B, 1998 tenecteplase versus accelerated t-PA in patients with acute ST-elevation myocardial infarction within 12 hours

inTIME 1, 1998 lanoteplase versus accelerated t-PA in patients within 6 hours of acute myocardial infarction

Zijlstra, 1997 primary ballon angioplasty versus streptokinase in atients with acute myocardial infarction

Garcia, 1997 primary ballon angioplasty versus accelerated t-PA in patients with anterior AMI

GUSTO 2B, 1997 primary ballon angioplasty versus accelerated t-PA in patients within 12 hours of acute myocardial infarction (with ST-segment elevation on the electrocardiogram)

GUSTO III, 1997 reteplase versus accelerated t-PA in patients within 6 hours after the onset of symptoms with ST-segment elevation or bundle-branch block

SESAM, 1997 saruplase versus t-PA in patients with acute myocardial infarction

COBALT, 1997 bolus t-PA versus accelerated t-PA in patients with acute myocardial infarction

Aronow , 1997 Propranolol versus control in patients >=62 years of age with New York Heart Association functional class II or III CHF, prior Qwave myocardial infarction, and a LV ejection fraction <40% after 2 months of treatment with diuretics and ACE inhibitors

Basu , 1997 Carvedilol versus placebo in Patients with acute MI <24h

Williams, 1997 warfarin versus placebo (on top of aspirin) in Acute MI, unstable angina

CARS (warafrin 3mg), 1997 warfarin versus control (on top of aspirin) in AMI

CARS (warfarin 1mg), 1997 warfarin versus control (on top of aspirin) in patients who had had myocardial infarction

FRAMI, 1997 Dalteparin versus placebo in patients with an acute MI, Q wave or STEMI

Su, 1997 versus in

ECCE, 1997 captopril versus placebo in patients with acute myocardial infarction

DANAMI-2, 1997 primary ballon angioplasty versus accelerated t-PA in patients who received thrombolytic treatment for a first acute myocardial infarction and with inducible myocardial ischemia (either symptomatic angina pectoris presenting spontaneously > 36 hours after admission or during a predischarge exercise test or ST changes during exercise compatible with ischemia)

DANAMI, 1997 invasive strategy versus concervative strategy in patients who received thrombolytic treatment for a first acute myocardial infarction and with inducible myocardial ischemia (either symptomatic angina pectoris presenting spontaneously > 36 hours after admission or during a predischarge exercise test or ST changes during exercise compatible with ischemia)

Akhras, 1997 primary ballon angioplasty versus streptokinase in patient within 12hr from onset of AMI

Kedev, 1997 primary ballon angioplasty versus in

Di Pasquale, 1997 captopril versus placebo in patients hospitalized for suspected anterior AMI within 4 h from the onset of symptoms suitable for thrombolysis

Grinfeld, 1996 primary ballon angioplasty versus streptokinase in

Ribichini, 1996 primary ballon angioplasty versus accelerated t-PA in

CRIS, 1996 verapamil versus placebo in patients admitted for acute myocardial infarction

Urek, 1996 magnesium versus placebo in patients with documented AMIbitm

RAPID-2, 1996 reteplase versus accelerated t-PA in patients with acute myocardial infarction within 12h from onset of ischemic chest pain

CATS, 1996 captopril versus placebo in patients with a first anterior myocardial infarction treated with intravenous streptokinase within 6h of onset of symptoms

INJECT, 1995 reteplase versus streptokinase in patients with symptoms and electrocardiographic criteria consistent with acute myocardial infarction within 12 h from onset of symptoms

Darasz , 1995 Xamoterol versus in patients after first Q-wave anterior myocardial infarction

ISIS-4, 1995 captopril versus placebo in Acute MI <24h of MI, no cardiogenic shock or persistent severe hypotension

CCS-1, 1995 captopril versus placebo in Acute MI <36h of MI

SMILE, 1995 zofenopril versus placebo in patients within 24 hours after a acute anterior myocardial infarction who were not undergoing thrombolysis

ISIS-4, 1995 magnesium versus control in patients entering 1086 hospitals up to 24 h (median 8 h) after the onset of suspected acute myocardial infarction with no clear contraindications4

Bhargava, 1995 magnesium versus placebo in proven AMI patients with chest pain of 1-6h

Shechter, 1995 magnesium versus placebo in suspected with AMI and considered unsuitable candidates for thrombolysis

Thogersen, 1995 magnesium versus placebo in patients with suspected AMI

Mounsey, 1995 repeat fibrinolysis versus no repeat fibrinolysis in patients with acute myocardial infarction and electrocardiographic evidence of failed reperfusion

Schulman, 1995 enalapril versus placebo in patients with an acute Q-wave AMI within 24 hours of symptom onset

STAR, 1995 recombinant staphylokinase versus t-PA in patients with evolving myocardial infarction of < 6 hours' duration and with ST-segment elevation

RAPID 1, 1995 t-PA versus t-PA in patients with acute myocardial infarction

ISIS-4, 1995 isosorbide mononitrate versus placebo in patients with suspected acute myocardial infarction up to 24h

Zwolle, 1994 primary ballon angioplasty versus streptokinase in patients with acute myocardial infarction

GREAT, 1994 Prehospital thrombolysis versus at hospital thrombolysis in

GISSI 3, 1994 lisinopril versus placebo in Acute MI <24h of MI

TOMIIS, 1994 late PTCA versus no PTCA in patients with a recent, first Q-wave myocardial infarction and an occluded infarct-related coronary artery

ATACS main, 1994 versus control (on top of aspirin) in Unstable angina,non–Q-wave MI

ASPECT, 1994 coumadin versus placebo in hospital survivors of myocardial infarction

DUCCS, 1994 UFH versus no heparin in patients with acute myocardial infarction four hours after APSAC administration, age <=85 y STEMI <=12 h

Abraham, 1994 versus in

Balkin, 1994 versus in

RESCUE, 1994 rescue PTCA versus no rescue PTCA in patients with first anterior wall infarction and angiographically demonstrated occluded infarct vessel within 8 hours of chest pain onset after thrombolysis

TAMI, 1994 rescue PTCA versus no rescue PTCA in

PRACTICAL (captopril), 1994 captopril or enalapril versus placebo in patients with acute myocardial infarction within 24 hours of onset

Ellis, 1994 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with first anterior wall infarction treated with any accepted intravenous thrombolytic regimen and angiographically demonstrated to have an occluded infarct vessel within 8 hours of chest pain onset

TIMI 4, 1994 accelerated t-PA versus APSAC in patients with acute myocardial infarction

ESPRIM, 1994 molsidomine versus placebo in patients with acute myocardial infarction within 24 h of symptom onset

GISSI-3, 1994 nitroglycerin versus control in patients with acute myocardial infarction

Di Pasquale, 1994 captopril versus placebo in patients with acute myocardial infarction , hospitalized within 4 h of the onset of symptoms

Ribeiro, 1993 primary ballon angioplasty versus streptokinase in patients with ST segment elevation within 6 h of the onset of chest pain

PAMI, 1993 primary ballon angioplasty versus t-PA in patients who presented within 12 hours of the onset of myocardial infarction

Gibbons, 1993 primary ballon angioplasty versus duteplase in patients with acute myocardial infarction

GUSTO tPA Hiv, 1993 accelerated t-PA versus streptokinase in Hommes et femmes

GUSTO tPA-SK Hiv, 1993 t-PA + streptokinase versus streptokinase in Hommes et femmes

MITI, 1993 (NCT00000468) Prehospital thrombolysis versus at hospital thrombolysis in

EMIP, 1993 Prehospital thrombolysis versus at hospital thrombolysis in

Van de Werf , 1993 Atenolol versus placebo in

SSSD , 1993 Metoprolol versus in Patients who have dah MI with LVEF of 20 to 45% and >=3 ventricular premature complexes per hour

SPRINT II, 1993 nifedipine versus placebo in men and women with suspected acute MI

French, 1993 flurbiprofen versus placebo in patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptoms

APRICOT, 1993 aspirin versus placebo in Patients treated with intravenous thrombolytic therapy followed by intravenous heparin and with patent infarct-related artery demonstrated at angiography within 48 hours

Centre Illinois, 1993 t-PA versus streptokinase in patients with AMI within 3h from onset of chest pain

LATE, 1993 t-PA versus placebo in patients with symptoms and electrocardiographic criteria consistent with AMI between 6 and 24 h from symptom onset

EMERAS (all delay), 1993 streptokinase versus placebo in patients entering hospital up to 24 h after the onset of suspected acute myocardial infarction

EMERAS (7-12h), 1993 streptokinase versus placebo in patients presenting 7-12 h from symptom onset

Ray, 1993 captopril versus placebo in haemodynamically stable patients with acute myocardial infarction, selected on clinical grounds as being at risk of late ventricular dilatation

Navarro-Lopez, 1993 early amiodarone versus control in patients who have had MI with a left ventricular ejection fraction of 20 to 45% and > or = 3 ventricular premature complexes per hour (pairs or runs) - 3 VPOs/h, pairs or runs of VT

Zijlstra , 1993 primary ballon angioplasty versus streptokinase in patients with acute myocardial infarction

duteplase 1, 1993 t-PA versus in patients with acute myocardial infarction

duteplase 2, 1993 t-PA versus duteplase in patients with evolving acute myocardial infarction

duteplase 3, 1993 t-PA versus duteplase in

Galcera, 1993 captopril versus placebo in patients with a first acute myocardial infarction and a pulmonary capillary pressure equal or above 17 mmHg

ISIS III (SK/APSAC), 1992 APSAC versus streptokinase in patients within 24 h of the onset of suspected acute myocardial infarction

ISIS III (SK/tPA), 1992 t-PA versus streptokinase in Hommes et femmes

SIAM, 1992 systematic ballon angioplasty versus no systematic angioplasty in patients treated by thrombolysis for AMI

TOPS, 1992 systematic ballon angioplasty versus no systematic angioplasty in patients with residual stenoses after thrombolytic treatment of myocardial infarction

Schwartz (high risk and low risk) , 1992 Oxprenolol versus placebo in patients surviving MI with or without complication by either ventricular tachycardia or fibrillation

CONSENSUS 2, 1992 enalapril versus placebo in patients with acute myocardial infarctions and blood pressure above 100/60 mm Hg, <24h of MI

SAMI (O’Neill), 1992 streptokinase versus primary intervention in symptom duration <4h

ECSG, 1992 UFH versus placebo in patients treated with alteplase thrombolysis for acute myocardial infarction, Age 21–70 y STEMI <=6h

OSIRIS, 1992 UFH versus placebo in STEMI w=6 h

Woods, 1992 magnesium versus placebo in patients with suspected AMI in the preceding 24h

Wu, 1992 magnesium versus control in suspected AMI

Cherng, 1992 t-PA versus streptokinase in patients with acute myocardial infarction

Ceremuzynski, 1992 early amiodarone versus placebo in No need for antiarrhythmic therapy

Rodriguez, 1992 amiodarone versus in Documented VT or VF

O'neill, 1992 angioplasty + streptokinase versus angioplasty in patients with evolving MI

TAMI 6, 1992 systematic ballon angioplasty versus no systematic angioplasty in

Belenkie, 1992 rescue PTCA versus no rescue PTCA in patients with a persistently occluded infarct artery following thrombolytic therapy more than 3 h after symptom onset

TAMI 6, 1992 t-PA versus placebo in patients with 6 to 24 hours of symptoms and ECG ST elevation

TEAM 3, 1992 APSAC versus t-PA in patient with ST elevalation within 4h of the onset of symptoms

TAPS, 1992 accelerated t-PA versus APSAC in patients with acute myocardial infarction.

RAAMI, 1992 accelerated t-PA versus t-PA in patients with acute myocardial infarction within 6h from onset of chest pain

Hildebrandt, 1992 isosorbide dinitrate versus placebo in patients with strong clinical and electrocardiographic suspicion of myocardial infarction within 8 hours after the onset of symptoms

Hargreaves, 1992 isosorbide mononitrate versus placebo in patients with acute myocardial infarction (systolic blood pressure > 90 mm Hg) within 24 hours of the start of pain

Bussmann, 1992 captopril versus placebo in patients with acute myocardial infarction

Hargreaves, 1992 captopril versus placebo in patients with acute myocardial infarction (systolic blood pressure > 90 mm Hg) within 24 hours of the start of pain

SWIFT, 1991 systematic ballon angioplasty versus no systematic angioplasty in patients presenting with clinical and electrocardiographic features of acute myocardial infarction up to three hours after the onset of major symptoms

Van den Brand, 1991 systematic ballon angioplasty versus no systematic angioplasty in suitable lesion

Curtis , 1991 Propranolol versus placebo in patients with recent infarction

McMurray , 1991 Xamoterol versus placebo in

Chen, 1991 magnesium versus placebo in patients with AMI

Feldstedt, 1991 magnesium versus placebo in patients, aged 75 y or less, with suspected AMI less than 8 h+—²

Shechter, 1991 magnesium versus placebo in patients with documented AMIbitm

KAMIT, 1991 t-PA half dose versus t-PA in patients within 6 hours of myocardial infarction

USIM, 1991 urokinase versus control in patients with acute myocardial infarction within 4 hours of the onset of pain

Sharpe, 1991 captopril versus placebo in patients with Q wave myocardial infarction, but without clinical heart failure 24-48h after onset of symptoms

Nabel, 1991 captopril versus placebo in patients with myocardial infarction

CAMIAT , 1991 early amiodarone versus placebo in patients with acute myocardial infarction within the previous 6-30 days and > 10 VPDs/h for 18 h or a run of VT

TAMI-5 (Califf), 1991 immediate systematic ballon angioplastyte versus no immediate angioplasty in patient with acute myocardial infarction

Belenkie, 1991 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with a patent infarct-related artery after thrombolytic therapy suitable for angioplasty

TAMI 5 (t-PA vs uroK), 1991 t-PA versus urokinase in patient with acute myocardial infarction

TEAM 2, 1991 anistreplase versus streptokinase in less than 76 years of age with electrocardiographic ST segment elevation who could be treated within 4 hours of symptom onset

TAMI 5 (t-PA+uroK vs tPA), 1991 t-PA + urokinase versus t-PA in patient with acute myocardial infarction

Bassand, 1991 t-PA versus APSAC in patients suffering from a first acute myocardial within 4 hours of the onset of symptoms

Zharov, 1991 error versus error in

GISSI II, 1990 t-PA versus streptokinase in patients with acute myocardial infarction within 6 h from onset of symptoms

International Study Group, 1990 t-PA versus streptokinase in patients with suspected acute myocardial infarction of less than 6 h duration

TEAHAT, 1990 Prehospital thrombolysis versus at hospital thrombolysis in

APSI, 1990 Acebutolol versus placebo in patient surviving MI at hight risk

DAVIT II, 1990 verapamil versus placebo in patients <76years with diagnosis of acute MI

ATACS pilot, 1990 versus control (on top of aspirin) in Unstable angina,non–Q-wave MI

Dutch-aspirin, 1990 aspirin versus placebo in patients with first anterior wall AMI

Roth, 1990 Prehospital thrombolysis versus at hospital thrombolysis in

Schofer, 1990 Prehospital thrombolysis versus at hospital thrombolysis in

Barbash, 1990 Prehospital thrombolysis versus at hospital thrombolysis in

Ising, 1990 magnesium versus placebo in patients with AMI

Parikka, 1990 magnesium versus placebo in patients with < 12 h from onset of chest pain AMImage/pj

Shechter, 1990 magnesium versus placebo in patients with admission diagnosis of AMI

Singh, 1990 magnesium versus placebo in patients suspected with AMI within 8-12h of the onset of MI

BASIS, 1990 early amiodarone versus control in patients with persisting asymptomatic complex arrhythmias after myocardial infarction (Lown class 3 or 4b in > 2 of 24 h)

Strasberg , 1990 amiodarone versus in Documented VT or VF unrelated to AMI

Barbash, 1990 systematic ballon angioplasty versus no systematic angioplasty in

Charvat, 1990 nitroglycerin versus placebo in patients with acute myocardial infarction and ST segment elevation on admission but no Q wave in the infarcted area within 6 hours of onset

Fitzgerald, 1990 isosorbide mononitrate versus placebo in patients with suspected acute myocardial infarction

DeWood, 1989 primary ballon angioplasty versus duteplase in

PRIMI (vs SK), 1989 saruplase versus streptokinase in patients with acute myocardial infarction were within 4 h of onset of symptoms

TIMI 2, 1989 systematic ballon angioplasty versus no systematic angioplasty in patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) within four hours of the onset of chest pain thought to be caused by myocardial infarction

TIMI IIB, 1989 versus placebo in

Johannessen, 1989 misc. versus control in

Castaigne , 1989 Prehospital thrombolysis versus at hospital thrombolysis in

Mcneill, 1989 Prehospital thrombolysis versus at hospital thrombolysis in

Ceremuzynski, 1989 magnesium versus placebo in patients with AMI within 12 h from onset of symptomslypj

PAIMS, 1989 t-PA versus streptokinase in patients with acute myocardial infarction less than 3 h old

White, 1989 t-PA versus streptokinase in patients with AMI

PRIMI (vs UK), 1989 saruplase versus urokinase in with a first acute myocardial infarction within 4 h of onset of symptoms

Erbel, 1989 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with acute transmural myocardial infarction

APSIM, 1989 APSAC versus control in patients with a first acute myocardial infarction within 5 h after the onset of symptoms

AIMS, 1988 APSAC versus placebo in Hommes et femmes, < 70 ans

ISIS-2 (SK), 1988 streptokinase versus placebo in patients within 24h of the onset of suspected acute myocardial infarction

ASSET, 1988 t-PA versus placebo in patient with suspected acute myocardial infarction

Western Washington Intravenous Trial, 1988 (NCT00000507) streptokinase versus placebo in Hommes et femmes, < ou = 75 ans

German Multicenter Trial, 1988 APSAC versus placebo in Hommes et femmes, < 70 ans

ECSG, 1988 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with acute myocardial infarction within 5 h after onset of symptoms

Lloyd , 1988 Sotalol versus placebo in

Ranganathan , 1988 Timolol versus placebo in

Kaul , 1988 Propranolol (iv) versus placebo in patients with uncomplecated myocardial infarction

Gottlieb, 1988 nifedipine versus placebo in

Erbel, 1988 nifedipine versus placebo in patients with acute myocardial infarction

SPRINT I, 1988 nifedipine versus placebo in patient surviving MI 7 and 21 days after admission

MDPIT, 1988 diltiazem versus placebo in Patient aged 25 to 75 years, admitted to coronary care units with a documented acute myocardial infarction

ISIS-2, 1988 aspirin versus placebo in suspected acute myocardial up to 24h

Huddinge, 1988 aspirin versus control in patients with acute myocardial infarction

Walker, 1988 nifedipine versus placebo in patients with suspected myocardial infarction within six hours from the onset of chest pain

Zannad, 1988 diltiazem versus placebo in

Wyse, 1988 IV lidocaine infusion versus placebo in suspected acute myocardial infarction

TIMI 2A, 1988 immediate systematic ballon angioplastyte versus no immediate angioplasty in patient thrombolyzed for a AMI

Beaufils, 1988 molsidomine versus placebo in patients with a first myocardial infarction within 6 hours from onset of symptoms

Jugdutt, 1988 nitroglycerin versus control in acute myocardial infarction

TAMI 1 pilot, 1987 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with acute myocardial infarction.

Guerci, 1987 systematic ballon angioplasty versus no systematic angioplasty in patients candidate to PTCA determined at the 1st day CA

Heber , 1987 Labetalol versus placebo in patients with suspected myocardial infarction

Yang , 1987 Betaxolol versus placebo in

LIT Research Group , 1987 Metoprolol versus placebo in patients, 45 to 74 yearsof age, surviving a recent acute MI

TIARA (Roqué), 1987 Timolol versus placebo in myocardialinfraction of less than 6 hours of evolution

Jaffe, 1987 nifedipine versus placebo in patients with acute myocardial infarction

ISIS-pilot, 1987 aspirin versus placebo in suspected acute myocardial infarction

Jones, 1987 dazoxiben versus control in

GRAND, 1987 GR3219B versus control in

ISIS-2 Pilot, 1987 UFH versus no heparin in patients with suspected MI <=24 h

Castaigne, 1987 Prehospital thrombolysis versus at hospital thrombolysis in

Abraham, 1987 magnesium versus placebo in patients with AMI

TIMI-1, 1987 (NCT00000505) t-PA versus streptokinase in patients with evolving acute myocardial infarction within 7 hr of the onset of symptoms

ISIS 2 pilot, 1987 streptokinase versus placebo in patients with suspected acute myocardial infarction

Hockings, 1987 early amiodarone versus placebo in patients with AMI - Absence of VF or VT > 3 beats

Topol, 1987 versus in patients with evolving transmural myocardial infarction

Topol, 1987 immediate systematic ballon angioplastyte versus no immediate angioplasty in patients with evolving transmural myocardial infarction

ISAM, 1986 streptokinase versus placebo in patients within six hours after the onset of symptoms of myocardial infarction

GISSI I, 1986 streptokinase versus placebo in patients within 12 h after the onset of symptoms and with no contraindications to SK

ISIS1 Collaborative Group , 1986 Atenolol versus placebo in patients within 5 h the onset of suspected acute myocardial infarction

Bradagan, 1986 nifedipine versus placebo in patients with suspected acute myocardial infarction within 6hrs

Gibson, 1986 diltiazem versus placebo in

Machecourt, 1986 diltiazem versus in

Dutch sulphinpyrazone, 1986 sulfinpyrazone versus control in

Rasmussen, 1986 magnesium versus placebo in patients with suspected AMIxbitm

Smith, 1986 magnesium versus placebo in patients with suspected AMI h.tm

TRENT (Wilcox), 1986 nifedipine versus placebo in patients with suspected myocardial infarction

O'Neill, 1986 primary ballon angioplasty versus intracoronary streptokinase in patients within 12 hours of their first symptoms of acute myocardial infarction

Mathey, 1985 urokinase versus error in patients with transmural acute myocardial infarction

MIAMI Trial Research Group , 1985 versus placebo in

Singh , 1985 Propranolol versus placebo in

Salathia , 1985 Metoprolol versus placebo in patients with acute myocardial infarction

Eisenberg, 1985 nifedipine versus placebo in patients with nontransmural myocardial infarction

Crea, 1985 verapamil versus placebo in patients admitted to the coronary care unit with transmural acute myocardial infarction

ECG ancillary EIS, 1985 versus in

Knudsen-A, 1985 ticlopidine versus control in patients with AMI

petri, 1985 versus in

Smith, 1985 versus in

ECSG, 1985 t-PA versus streptokinase in patients with acute myocardial infarction of less than 6 h duration

Loogna, 1985 nifedipine versus placebo in patients with acute myocardial infarction within 6 h from onset of symptoms

Eichler, 1985 Tiapamil versus control in

Dunn, 1985 IM lidocaine (without infusion) versus placebo in suspected acute myocardial infarction within 6 hours of the onset of sympto

Koster and Dunning, 1985 IM lidocaine (without infusion) versus control in suspected acute myocardial infarction

Campbell , 1984 Timolol versus placebo in

Federman , 1984 Timolol versus placebo in

Gupta , 1984 Propranolol versus placebo in

ICSG , 1984 Timolol versus placebo in patients within four hours after onset of symptoms of myocardial infarction

Norris , 1984 Propranolol versus placebo in

Owensby , 1984 Pindolol versus placebo in

Roberts , 1984 Propranolol versus placebo in

EIS , 1984 Oxprenolol versus placebo in patients 35 to 69 years whohas survived acute myocardial infarction

Mazur , 1984 Propranolol versus in myocardial infarction within the last 3 months, aged <62 years

Muller, 1984 nifedipine versus in

Gordon, 1984 nifedipine versus in

Bussman, 1984 verapamil versus control in

DAVIT I, 1984 verapamil versus placebo in

Morton, 1984 magnesium versus placebo in patients with AMI within 8 h of onsetmag

Danish study, 1984 verapamil versus placebo in patients under 75 years of age admitted to the CCU with a suspicion of acute myocardial infarction

Sirnes, 1984 nifedipine versus placebo in patients with suspected acute myocardial infarction

Lis, 1984 nitroglycerin versus placebo in patients with acute myocardial infarction

Nigam , 1983 Propranolol versus placebo in

UKCSG , 1983 Timolol versus placebo in

Australian and Swedish study, 1983 Pindolol versus placebo in patients who had electrical and/or mechanical complications after an acute myocardial infarction

Manger Cats , 1983 Metoprolol versus placebo in MI, NYHA Class I or II and <=70 y

Rehnqvist , 1983 Metoprolol versus placebo in AMI patients <70 years in sinus rythm without complete BBB

Louvain sulphinpyrazone, 1983 sulfinpyrazone versus placebo in recent myocardial infarction

Flaherty, 1983 nitroglycerin versus placebo in patients with acute myocardial infarction

Nelson, 1983 nitroglycerin versus control in men with radiographic and haemodynamic evidence of left ventricular failure following acute myocardial infarction

Jaffe, 1983 nitroglycerin versus placebo in patients with inferior infarction under conventional clinical conditions within 10 hours of the onset of symptoms

Jugdutt, 1983 nitroglycerin versus control in patients with acute myocardial infarction

Azancot, 1982 Acebutolol versus placebo in patients seen within 24 hours after the onset of uncomplicated anterior transmural myocardial infarction

Gupta , 1982 Propranolol versus placebo in

Von Essen , 1982 versus placebo in

BHAT , 1982 (NCT00000492) Propranolol versus placebo in mean and women who has experienced at least one MI

Hansteen , 1982 Propranolol versus placebo in high-risk patients who survived acute myocardial infarction

Julian , 1982 Sotalol versus placebo in patients surviving an acute myocardial infarction

Taylor , 1982 Oxprenolol versus placebo in Men 35 to 65 years old who had an acute myocardial infarction between 1 and 90 months reviously

EPSIM, 1982 any anticoagulant versus aspirin in patients surviving myocardial infarction

Durrer, 1982 nitroprusside versus placebo in patients with typical acute myocardial infarction

Cohn, 1982 nitroprusside versus placebo in men with presumed acute myocardial infarction and left ventricular filling pressure of at least 12 mm Hg

CPRG , 1981 Oxprenolol versus placebo in

Tonkin , 1981 Timolol versus placebo in

Hjalmarson , 1981 Metoprolol versus placebo in patients aged between 40 -74 years with suspected MI and onset of infarction within the previous 48h

Norwegian Multicentre Study Group , 1981 Timolol versus placebo in patients surviving acute myocardial infarction

Hockings, 1981 nitroprusside versus control in patients with a mean pulmonary capillary wedge pressure of more than 20 mm Hg within 24 hours of acute infarction

Bussman, 1981 nitroglycerin versus control in patients with acute myocardial infarction within 24 hours

Johansson , 1980 Practolol versus placebo in

Macleod , 1980 Practolol versus placebo in

Mueller , 1980 Propranolol versus placebo in

Snow , 1980 Practolol versus placebo in

Wilcox , 1980 Oxprenolol versus placebo in

Yusuf , 1980 Atenolol versus placebo in

Baber , 1980 Propranolol versus placebo in Men and women with anterior MI

Rehnqvist , 1980 versus in

Wilcox , 1980 Propranolol or atenolol versus placebo in patients with acute MI within the past 24 hours

Wilcox, 1980 sulfinpyrazone versus placebo in patients with acute myocardial infarction

Sixty Plus reinfarction Study, 1980 any anticoagulant versus placebo in over 60 years of age

German-Austrian Study Group (oac vs asp), 1980 phenprocoumon versus aspirin in patients who had survived a myocardial infarction for 30-42 days

German-Austrian Study Group (oac vs pbo), 1980 phenprocoumon versus placebo in patients who had survived a myocardial infarction for 30-42 days

Hutton , 1979 Propranolol versus placebo in

Lombardo , 1979 Oxprenolol versus placebo in

Thompson , 1979 Practolol versus placebo in

Andersen , 1979 Alprenolol versus placebo in patients years with definite or suspected myocardial infarction

Yusuf , 1979 Atenolol versus placebo in patient ager 46-70 with recent transmural myocardial infarct

MI study group, 1979 nifedipine versus in

Chiche, 1979 nitroglycerin versus control in patients with suspected myocardial infarction, within 12 h of the onset

Evemy , 1978 Practolol versus placebo in

Norris , 1978 Propranolol versus placebo in

Peter , 1978 Propranolol versus placebo in

Lie (IM), 1978 IM lidocaine (without infusion) versus placebo in suspected acute myocardial infarction

Barber , 1976 Propranolol versus placebo in

Pitt , 1976 Propranolol versus placebo in

Frankfurt, 1976 aspirin versus control in

Singh and Kocot, 1976 IM lidocaine (without infusion) versus placebo in suspected acute myocardial infarction

Waagstein , 1975 Practololormetoprolol versus placebo in

Multicentre international , 1975 Practolol versus placebo in patients recovering from acute myocardial infarction

Ahlmark , 1974 Alprenolol versus in patients admitted with suspected MI

Wilhelmsson , 1974 Alprenolol versus placebo in patient aged 57-67 years discharge alive after acute myocardial infarction

Lie (IV), 1974 IV lidocaine infusion versus placebo in suspected acute myocardial infarction

Reynolds , 1972 Alprenolol versus placebo in patient with suspected MI

Darby, 1972 IV lidocaine infusion versus control in suspected acute myocardial infarction

Baker, 1971 IV lidocaine infusion versus placebo in suspected acute myocardial infarction

Chopra, 1971 IV lidocaine infusion versus placebo in suspected acute myocardial infarction

Pitt, 1971 IV lidocaine infusion versus control in suspected acute myocardial infarction

Bennett, 1970 IV lidocaine infusion versus control in suspected acute myocardial infarction

Dotremont , 1968 Propranolol versus placebo in

Fuccella , 1968 Oxprenolol versus placebo in

Kahler , 1968 Propranolol versus placebo in

Ledwich , 1968 Propranolol versus placebo in

Norris , 1968 Propranolol versus placebo in

Gent-AMI, 1968 misc. versus control in

Sloman , 1967 Propranolol versus placebo in

Barber , 1967 Practolol versus placebo in patient admitted to a CCU with suspected acute myocardial infarction

Balcon , 1966 Propranolol versus placebo in

Clausen , 1966 Propranolol versus placebo in

Multicentre , 1966 Propranolol versus placebo in

CLARITY, 0 versus in

OASIS pilot phase 2, 0 versus in Unstable angina, non–Q-wave MI

Kostuk and Beanlands, 0 IV lidocaine infusion versus placebo in suspected acute myocardial infarction

O, 0 IV lidocaine infusion versus placebo in suspected acute myocardial infarction

Sandlar, 0 IM lidocaine (without infusion) versus placebo in suspected acute myocardial infarction

LoWASA (copie de 8025), 0 versus in

PIHRATE, 0 (NCT00377650) aspiration thrombectomy versus primary percutaneous coronary intervention in patients with STEMI <6hr; ST elevation >3mm in at leat one lead; TIMI 0 or 1 in infract related arteries

TIMI II-A (defered), 0 systematic ballon angioplasty versus no systematic angioplasty in

STOPAMI 4, 0 primary stenting versus balloon angioplasty in patients with AMI referred for failed thrombolysis performed within the previous 24 h

EXPIRA, 0 versus in

MILIS, 0 (NCT00000493) error versus placebo in myocardial infarction

Heng, GIK infusion versus in

Stanley, GIK infusion versus in

Rogers, GIK infusion versus in

Satler, GIK infusion versus in

Mittra, GIK infusion versus in

Pitcher, GIK infusion versus in

Pentecost, GIK infusion versus in

MRC, GIK infusion versus in

Hjermann, GIK infusion versus in

Chevalier, error versus error in

IMMEDIATE, (NCT00091507) GIK infusion versus placebo in patients with threatened or established acute myocardial infarction

GLOBAL, (NCT00125645) irbesartan versus control in patients with acute myocardial infarction, a wall motion score >1.3 (EF>0.40) and signs of diastolic dysfunction

APRICOT-3, (NCT00138034) routine invasive strategy versus ischemia-guided strategy in Successful Thrombolysis for Suspected Acute Myocardial Infarction

CRIT Pilot, (NCT00126334) liberal blood transfusion strategy versus conservative in acute myocardial infarction with presentation within 72 hours of randomization (acute myocardial infarction is defined as ischemic-type chest discomfort lasting at least 30 minutes associated with creatinine kinase MB or troponin >upper limit of normal); admission to CCU; hematocrit .30 or less

TRANSFER-AMI à effacer, (NCT00164190) error versus error in

CADUCEUS, (NCT00893360) cardiosphere-derived stem cells versus control in patients with ischemic left ventricular dysfunction and a recent myocardial infarction

OPTIMAAL, versus in

Nouvel essai, versus in

REGENT (Wojakowski), (NCT00316381) error versus error in

Ogawa, (NCT00265239) Edaravone versus placebo in

TRIANA, (NCT00257309) Thrombolysis versus Primary Angioplasty in AMI in patients >=75 years old with ST-segment elevation or LBBB AMI <6 hours of evolution

NCT00975234, (NCT00975234) Autologous Skeletal Myoblasts versus placebo in Patients With Old Myocardial Infarction

Export study, error versus error in

MARVEL, percutaneous skeletal-myoblast cell therapy versus placebo in patients with post-MI myocardial scarring

TIME, autologous bone marrow stem cells versus placebo in patients with moderate-to-large anterior AMIs who have undergone successful percutaneous coronary intervention of the left anterior descending coronary artery and have a left ventricular (LV) ejection fraction

INNOVATE, (NCT00751231) elinogrel versus error in

ENACT-AMI, E-CMM versus placebo in

REVEAL, (NCT00378352) erythropoietin versus placebo in patients after large myocardial infarction

REVIVAL-3, (NCT00390832) recombinant human erythropoietin beta versus placebo in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention

TROPHI, thrombectomy versus conventional PCI in

MUSTELLA, thrombectomy versus conventional PCI in

NAVIGATE ESUS, 2018 (NCT02313909) rivaroxaban versus aspirin in patients with recent ischemic stroke that was presumed to be from cerebral embolism but without arterial stenosis, lacune, or an identified cardioembolic source

VITATOPS, 2010 (NCT00097669ÐX&) folic acid, vit B12 and vit B6 versus placebo in patients with recent stroke or TIA (within the past seven months)

CLOSURE I, 2010 (NCT00201461) Starflex versus medical treatment in patients with a stroke and/or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale

PROFESS, 2008 telmisartan versus placebo in

Bonaa , 2006 folic acid versus placebo in patients who had had an acute myocardial infarction

Lonn, 2006 folic acid versus error in patients 55 years of age or older who had vascular disease or diabetes

Zoungas, 2006 folic acid versus error in patients with chronic renal failure

SPARCL, 2006 (NCT00147602) atorvastatin versus placebo in patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 2.6 to 4.9 mmol per liter, and had no known coronary heart disease

Righetti, 2006 folic acid versus error in hemodialysis patients

VISP (Toole), 2004 high dose - folic acid, vit B12 and vit B6 versus low dose - folic acid, vit B12 and vit B6 in adults with nondisabling cerebral infarction

HPS (post troke sub group), 2004 simvastatin versus placebo in adults with cerebrovascular disease, total cholesterol >=3·5 mmol/L and without coronaro disease (n=1820)

Wrone , 2004 high dose versus low dose in patients with end-stage renal disease

TAPIRSS, 2004 versus in patients with ischemic stroke or TIA within 6 months

Liem, 2003 folic acid versus error in patients with stable coronary artery disease

TIM, 2000 triflusal versus aspirin in AMI within less than 24 h of symptom onsete

LHSPS, 1999 anticoagulant versus no anticoagulant in